COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN US REDUCE-IT PATIENTS
Open accessAbstract
The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) showed that among US patients with elevated triglyceride levels on statin therapy (n=3,146), the risk of cardiovascular disease events was reduced by 31% in those randomized to 4g of icosapent ethyl daily
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cited by
Sorted by citations
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109 · see citing works
Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids
Weinberg, R. L., Brook, R. D., Rubenfire, M., & Eagle, K. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.060 · Cited by 63 · see citing works
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07310-y · Cited by 23 · see citing works
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01173-3 · Cited by 20 · see citing works
- Authors
- Weintraub, W. S., Bhatt, D., Zhang, Z., Zhang, C., Sarahfaye, D., Boden, W. E., Steg, P. G., Miller, M., Brinton, E., King, J., Bress, A., Jacobson, T., Tardif, J. C., Ballantyne, C. M., & Kolm, P.
- Affiliations
- MedStar Washington Hospital Center (US)
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 75
- Issue
- 11
- Pages
- 1914
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W3010882329
- Semantic Scholar
- daa2f9071cd2231a56a9446ec93b0978ab2b8988
- Cited by
- 13
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 2
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- icosapent ethyl, REDUCE-IT trial, cost-effectiveness, hypertriglyceridemia, statin therapy, cardiovascular events, omega-3 fatty acids, triglyceride elevation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
